Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:activeIngredient |
gptkb:tisagenlecleucel
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States gptkb:FDA 2017 diffuse large B-cell lymphoma B-cell acute lymphoblastic leukemia |
| gptkbp:ATCCode |
L01XL08
|
| gptkbp:cost |
high
|
| gptkbp:developedBy |
gptkb:Novartis
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kymriah
|
| gptkbp:indication |
relapsed or refractory diffuse large B-cell lymphoma in adults
relapsed or refractory B-cell precursor acute lymphoblastic leukemia in patients up to 25 years |
| gptkbp:mechanismOfAction |
genetically modified autologous T cells targeting CD19
|
| gptkbp:orphanDrugStatus |
yes
|
| gptkbp:requires |
hospitalization for administration
pre-treatment lymphodepleting chemotherapy |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
infections
cytokine release syndrome hypogammaglobulinemia neurological toxicities |
| gptkbp:storage |
cryopreserved
|
| gptkbp:target |
gptkb:CD19
|
| gptkbp:type |
autologous cellular immunotherapy
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|